re: Ann: Strategic milestone underpins US rev... Now surely a company generating over $30m in global sales , spends $5m a year in R&D and has just realeased a number of new products is worth much more than $15m
Net debt is almost zero and cashflow supports its growth also if the business were sold it would go for 1.5 to 2 times sales.
We could compare them with numerous other medical device companies who have similar market caps but have virtually no sales and need capital.
re: Ann: Strategic milestone underpins US rev... Now surely a...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.025(8.47%) |
Mkt cap ! $61.50M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 32.0¢ | 29.0¢ | $132.1K | 428.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 50000 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 21999 | 3 |
View Market Depth
| Last trade - 16.10pm 28/07/2025 (20 minute delay) ? |
| CMP (ASX) Chart |